Inventiva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

15.02.24	Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 (GlobeNewswire)
24.01.24	Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
10.01.24	Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank (GlobeNewswire)
20.12.23	Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program (GlobeNewswire)
04.12.23	Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH (GlobeNewswire)
21.11.23	Inventiva reports 2023 Third Quarter Financial Information¹ (GlobeNewswire)
06.11.23	Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023 (GlobeNewswire)
28.09.23	Inventiva reports its 2023 first-half financial results and provides a corporate update (GlobeNewswire)
20.09.23	Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea (GlobeNewswire)
31.08.23	Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certifica (GlobeNewswire)
27.07.23	Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update (GlobeNewswire)
24.06.23	Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association (GlobeNewswire)
13.06.23	Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD (GlobeNewswire)
08.06.23	Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients (GlobeNewswire)
07.06.23	Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023 (GlobeNewswire)
26.05.23	Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023 (GlobeNewswire)
25.05.23	Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China (GlobeNewswire)
25.05.23	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023 (GlobeNewswire)
16.05.23	Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update (GlobeNewswire)
04.05.23	Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023 (GlobeNewswire)
04.05.23	Combined General Meeting of May 25, 2023. Availability of the preparatory documents (GlobeNewswire)
30.03.23	Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F (GlobeNewswire)
29.03.23	Inventiva reports its 2022 full-year results (GlobeNewswire)
23.03.23	Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results (GlobeNewswire)
14.02.23	Inventiva reports preliminary financial results for Full-Year 2022¹ (GlobeNewswire)
21.11.22	Inventiva announces a new Director of the Board of Directors (GlobeNewswire)
10.11.22	Inventiva reports 2022 Third Quarter Financial Information¹ (GlobeNewswire)
31.10.22	Inventiva provides an update on the development of cedirogant by AbbVie (GlobeNewswire)
21.10.22	Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022 (GlobeNewswire)
22.09.22	Inventiva reports its 2022 first-half financial results and provides a corporate update (GlobeNewswire)
21.09.22	Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China (GlobeNewswire)
07.09.22	Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results (GlobeNewswire)
28.07.22	Inventiva Reports 2022 First-Half Financial Information¹ (GlobeNewswire)
07.07.22	Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D (GlobeNewswire)
04.07.22	Update on Inventiva's cash position and on the finance documentation with the European Investment Bank (GlobeNewswire)
16.06.22	Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022 (GlobeNewswire)
09.06.22	Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022 (GlobeNewswire)
07.06.22	Inventiva joins the Euronext Tech Leaders segment (GlobeNewswire)
03.06.22	Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association (GlobeNewswire)
23.05.22	Inventiva announces participation at several investors conferences in May and June 2022 (GlobeNewswire)
19.05.22	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022 (GlobeNewswire)
16.05.22	Inventiva reports 2022 First Quarter Financial Information and provides clinical development update (GlobeNewswire)
16.05.22	Inventiva secures a €50 million credit facility from the European Investment Bank (GlobeNewswire)
28.04.22	Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022 (GlobeNewswire)
28.04.22	Combined General Meeting of May 19, 2022 - Availability of the preparatory documents (GlobeNewswire)
07.04.22	Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver (GlobeNewswire)
08.03.22	Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA (GlobeNewswire)
07.03.22	Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis (GlobeNewswire)
01.03.22	Inventiva announces participation at several conferences in March 2022 (GlobeNewswire)
28.02.22	Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Geberit	600.60	2.67 %	K V
Kuehne+Nagel Int	191.90	2.21 %	K V
Swiss Re	148.10	1.20 %	K V
Sonova Hldg	272.30	1.19 %	K V
Holcim	98.18	1.09 %	K V
CieFinRichemont	155.50	-0.32 %	K V
Lonza Grp	570.60	-0.56 %	K V
Novartis	89.34	-0.84 %	K V
Roche Hldg G	254.50	-1.74 %	K V
Alcon	73.16	-7.63 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Inventiva Aktie VALOR 35598121 / ISIN FR0013233012

Nachrichten zu Inventiva SA act ord

Aktien Top/Flop

Meistgelesene Nachrichten